title: Cancer nanomedicine: from targeted delivery to combination therapy.
abstract: The advent of nanomedicine marks an unparalleled opportunity to advance the treatment of various diseases, including cancer. The unique properties of nanoparticles (NPs), such as large surface-to-volume ratio, small size, the ability to encapsulate various drugs, and tunable surface chemistry, give them many advantages over their bulk counterparts. This includes multivalent surface modification with targeting ligands, efficient navigation of the complex in vivo environment, increased intracellular trafficking, and sustained release of drug payload. These advantages make NPs a mode of treatment potentially superior to conventional cancer therapies. This review highlights the most recent developments in cancer treatment using NPs as drug delivery vehicles, including promising opportunities in targeted and combination therapy.
authors: Laboratory of Nanomedicine and Biomaterials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Chemical, Biological and Pharmaceutical Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA. Electronic address: xiaoyang@njit.edu.
authors: Xiaoyang
authors: X
authors: Xu
authors: Laboratory of Nanomedicine and Biomaterials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
authors: William
authors: W
authors: Ho
authors: Laboratory of Nanomedicine and Biomaterials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
authors: Xueqing
authors: X
authors: Zhang
authors: Laboratory of Nanomedicine and Biomaterials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
authors: Nicolas
authors: N
authors: Bertrand
authors: Laboratory of Nanomedicine and Biomaterials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: ofarokhzad@zeus.bwh.harvard.edu.
authors: Omid
authors: O
authors: Farokhzad
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy / Q000379:methods*; D003692:Delayed-Action Preparations; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry; D009369:Neoplasms / Q000628:therapy*; D034622:RNA Interference
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers
keywords: cancer; combination therapy; nanomedicine; targeted delivery
references: N Engl J Med. 2013 Aug 29;369(9):819-29
references: 23984729
references: Nanomedicine (Lond). 2013 May;8(5):687-98
references: 23075285
references: Nat Rev Drug Discov. 2008 Sep;7(9):771-82
references: 18758474
references: Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18638-43
references: 24167294
references: Nature. 2010 Apr 15;464(7291):1067-70
references: 20305636
references: Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
references: 2946403
references: Cancer Discov. 2013 Nov;3(11):1302-15
references: 24002999
references: Sci Transl Med. 2012 Apr 4;4(128):128ra39
references: 22491949
references: Adv Drug Deliv Rev. 2013 Nov;65(11-12):1496-532
references: 23933616
references: Handb Exp Pharmacol. 2010;(197):55-86
references: 20217526
references: Nat Nanotechnol. 2007 Dec;2(12):751-60
references: 18654426
references: Clin Cancer Res. 2009 Jan 15;15(2):692-700
references: 19147776
references: Mol Pharm. 2009 May-Jun;6(3):659-68
references: 19267452
references: Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20792-7
references: 21068378
references: Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10980-5
references: 21690347
references: ACS Nano. 2012 May 22;6(5):4279-87
references: 22471841
references: Nat Rev Drug Discov. 2003 Mar;2(3):214-21
references: 12612647
references: Nanomedicine (Lond). 2011 Jun;6(4):715-28
references: 21718180
references: Cancer Metastasis Rev. 2008 Dec;27(4):655-64
references: 18523731
references: Drug Deliv Transl Res. 2014 Feb;4(1):74-83
references: 25786618
references: Annu Rev Biomed Eng. 2012;14:1-16
references: 22524388
references: PLoS One. 2013;8(3):e58619
references: 23505544
references: Chem Soc Rev. 2013 Sep 7;42(17):7289-325
references: 23549663
references: Science. 2013 Feb 22;339(6122):971-5
references: 23430657
references: Adv Drug Deliv Rev. 2013 Jan;65(1):80-8
references: 23036224
references: Angew Chem Int Ed Engl. 2011 Jul 25;50(31):7027-31
references: 21698724
references: Colloids Surf B Biointerfaces. 2000 Oct 1;18(3-4):301-313
references: 10915952
references: Proc Natl Acad Sci U S A. 2012 May 22;109(21):8230-5
references: 22547809
references: Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 Jul-Aug;3(4):421-37
references: 21538941
references: J Clin Oncol. 2006 Jun 20;24(18):2786-92
references: 16782917
references: Adv Drug Deliv Rev. 2011 Mar 18;63(3):152-60
references: 20840859
references: Biomaterials. 2011 Sep;32(26):6226-33
references: 21658757
references: ACS Nano. 2013 Nov 26;7(11):9518-25
references: 24274814
references: Adv Drug Deliv Rev. 2013 Jan;65(1):71-9
references: 23088862
references: Biomacromolecules. 2014 May 12;15(5):1845-51
references: 24670217
references: Adv Drug Deliv Rev. 2011 Jul 18;63(8):623-39
references: 21144874
references: ACS Nano. 2013 Dec 23;7(12):10671-80
references: 24215426
references: Adv Drug Deliv Rev. 2011 Mar 18;63(3):170-83
references: 20965219
references: RNA. 2006 Jun;12(6):988-93
references: 16611941
references: J Pharm Sci. 1995 Apr;84(4):493-8
references: 7629743
references: Invest New Drugs. 2013 Aug;31(4):986-1000
references: 23397498
references: Nat Chem. 2012 Jan;4(1):59-63
references: 22169873
references: Nanomedicine. 2014 Feb;10(2):401-9
references: 23969105
references: ACS Nano. 2012 Aug 28;6(8):6667-74
references: 22872125
references: Nat Rev Drug Discov. 2009 Feb;8(2):129-38
references: 19180106
references: Eur J Pharm Biopharm. 2009 Mar;71(3):409-19
references: 19070661
references: Biomaterials. 1999 Jul;20(14):1269-75
references: 10403044
references: Cancer Discov. 2013 Apr;3(4):406-17
references: 23358650
references: ACS Nano. 2014 Jun 24;8(6):6056-65
references: 24824296
references: Lancet Oncol. 2006 Sep;7(9):719-27
references: 16945766
references: ACS Nano. 2009 Jan 27;3(1):16-20
references: 19206243
references: Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20786-91
references: 21068376
references: J Clin Oncol. 2011 Mar 10;29(8):979-85
references: 21282541
references: Nat Biotechnol. 2010 Feb;28(2):172-6
references: 20081866
references: Adv Drug Deliv Rev. 2011 Mar 18;63(3):131-5
references: 20304019
references: Adv Drug Deliv Rev. 2012 Oct;64(13):1363-84
references: 22917779
references: Adv Drug Deliv Rev. 2013 Nov;65(13-14):1784-802
references: 23880506
references: Adv Drug Deliv Rev. 2011 Mar 18;63(3):136-51
references: 20441782
references: Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5572-6
references: 2062838
references: Adv Mater. 2012 Oct 23;24(40):5476-80
references: 22886872
references: J Am Chem Soc. 2013 May 29;135(21):7933-7
references: 23631388
references: Nat Nanotechnol. 2012 Oct;7(10):623-9
references: 23042546
references: Sci Transl Med. 2013 Dec 18;5(216):216rv4
references: 24353161
references: J Control Release. 1999 Jun 28;60(1):121-8
references: 10370176
references: Pharm Res. 2011 Feb;28(2):215-36
references: 20721603
references: Expert Opin Ther Targets. 2005 Dec;9(6):1179-87
references: 16300469
references: Int J Nanomedicine. 2014;9:467-83
references: 24531078
references: Adv Mater. 2013 May 14;25(18):2536-41
references: 23526714
references: Adv Mater. 2011 Nov 2;23(41):4770-5
references: 21932280
references: J Control Release. 2012 Jun 10;160(2):117-34
references: 22484195
references: Chem Soc Rev. 2012 Apr 7;41(7):2971-3010
references: 22388185
references: Int J Cancer. 2010 May 1;126(9):2036-48
references: 19739117
references: Adv Drug Deliv Rev. 2014 Feb;66:2-25
references: 24270007
references: Eur J Pharm Sci. 2013 Feb 14;48(3):416-27
references: 23262059
references: J Control Release. 2012 Jul 20;161(2):164-74
references: 22516097
references: Nature. 2006 Jul 27;442(7101):368-73
references: 16871203